Imipramine on ER+ve and Triple Negative Breast Cancer
Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Breast Cancer
DRUG: Imipramine
Decrease in the proliferation rate of triple negative breast cancer, 30 days
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.